toremifene sold brand name fareston among others medication used treatment advanced breast cancer postmenopausal taken side effects toremifene include hot flashes sweating nausea vomiting dizziness vaginal discharge vaginal also cause blood clots irregular heartbeat cataracts visual disturbances elevated liver enzymes endometrial hyperplasia endometrial high blood calcium levels occur women bone medication selective estrogen receptor modulator serm hence mixed estrogen receptor er biological target estrogens like estrogenic effects bone liver uterus antiestrogenic effects triphenylethylene derivative closely related toremifene introduced medical use first antiestrogen introduced since tamoxifen available generic medication united toremifene approved treatment metastatic breast cancer postmenopausal women estrogen receptorpositive unknownstatus approved use united shows equivalent effectiveness tamoxifen toremifene found effective treatment breast pain may effective medication tamoxifen also superior effects bone mineral density lipid profile including levels cholesterol triglycerides compared toremifene reported significantly improve symptoms gynecomastia toremifene provided form mg oral side effects toremifene similar common side effect hot side effects include sweating nausea vomiting dizziness vaginal discharge vaginal women bone metastases hypercalcemia may toremifene small risk thromboembolic cataracts vision changes elevation liver enzymes drug prolongs qt interval hence risk potentially fatal risk dysrhythmias reduced avoiding use patients hypokalemia hypomagnesemia preexisting qt prolongation taking qtprolonging toremifene estrogenic actions uterus increase risk endometrial hyperplasia endometrial toremifene appears safer lower risk venous thromboembolism vte eg pulmonary embolism stroke lower risk vte may related fact tamoxifen decreases levels antithrombin iii significantly greater extent either mgday toremifene substrate cytochrome enzyme hence drugs induce inhibit enzyme respectively decrease increase levels toremifene toremifene selective estrogen receptor modulator selective mixed estrogen receptors ers estrogenic actions tissues antiestrogenic actions medication estrogenic effects bone partial estrogenic effects uterus liver antiestrogenic effects affinity toremifene er similar studies using rat er toremifene tamoxifen affinity estradiol affinities ki toremifene human ers reported nm erα nm rat er studies toremifene affinity estradiol er metabolites ndesmethyltoremifene affinity estradiol er affinity another metabolite showed higher antiestrogenic potency toremifene vitro one also found strongly antiestrogenic metabolites toremifene particularly may contribute importantly clinical activity hand authorities consider toremifene toremifene similar tamoxifen shares indications toremifene may safer tamoxifen hepatocarcinogen animals may less potential however clinical studies found significant differences toremifene tamoxifen including terms effectiveness tolerability safety hence clinical use toremifene somewhat toremifene thought onethird potency tamoxifen ie mg toremifene roughly equivalent mg tamoxifen treatment breast toremifene found antigonadotropic effects postmenopausal progonadotropic effects increase sex hormonebinding globulin decrease insulinlike growth factor levels postmenopausal women addition activity serm antagonist estrogenrelated receptor γ bioavailability toremifene precisely determined known good estimated approximately levels toremifene steady state dosage mgday levels ndesmethyltoremifene steady state toremifene ngml mgday ngml mgday ngml levels steady state toremifene ngml mgday ngml concentrations toremifene increase linearly across dose range toremifene bound plasma proteins bound specifically albumin globulin fraction fraction albumin apparent volume distribution toremifene ranged toremifene metabolized liver primarily undergoes secondary metabolites toremifene include ndesmethyltoremifene among ospemifene deaminohydroxytoremifene also major metabolite elimination halflife toremifene days healthy people impaired liver function halflife elimination halflives metabolites toremifene days ndesmethyltoremifene days days long elimination halflives toremifene metabolites thought due enterohepatic recirculation high plasma protein toremifene eliminated feces toremifene also known derivative triphenylethylene close analogue also closely related afimoxifene ospemifene toremifene introduced united states first antiestrogen introduced country since tamoxifen toremifene generic name drug inntooltip international nonproprietary name bantooltip british approved name toremifene citrate usantooltip united states adopted name jantooltip japanese accepted name torémifène dcftooltip dénomination commune toremifene marketed almost exclusively brand name toremifene marketed widely throughout world available united states united kingdom ireland many european countries south africa australia new zealand elsewhere throughout toremifene also evaluated prevention prostate cancer tentative brand name pharmaceutical company gtx inc conducting two different phase clinical trials first pivotal phase clinical trial treatment serious side effects androgen deprivation therapy adt especially vertebralspine fractures hot flashes lipid profile gynecomastia advanced prostate cancer second pivotal phase iii clinical trial prevention prostate cancer high risk men high grade prostatic intraepithelial neoplasia pin results trials expected first quarter nda first application relief prostate cancer adt side effects submitted feb oct fda said would need clinical data eg another phase iii ultimately development discontinued toremifene never marketed complications associated adt treatment prevention prostate toremifene may useful prevention bicalutamideinduced doubleblind placebocontrolled randomized year clinical trial toremifene conducted using sample men subjects median age years diagnosed highgrade prostatic intraepithelial neoplasia hgpin considered premalignant though thompson leach feel low grade pin could also deemed sponsor gtx designed managed study found placebo toremifene groups cancer events distinction found gleason scores either previous murine studies using transgenic adenocarcinoma mouse prostate tramp mice showed toremifene prevented palpable tumors animals study used toremifene early prophylactic differentiates phase iii human httpsenwikipediaorgwikitoremifene